Ochratoxin B¹³C₂₀

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-220. [Content Brief]

[2]. Knasmüller S, et al. Structurally related mycotoxins ochratoxin A, ochratoxin B, and citrinin differ in their genotoxic activities and in their mode of action in human-derived liver (HepG2) cells: implications for risk assessment. Nutr Cancer. 2004;50(2):190-7. [Content Brief]

[3]. O'Brien E, et al. Investigation of the teratogenic potential of ochratoxin A and B using the FETAX system. Birth Defects Res B Dev Reprod Toxicol. 2005 Oct;74(5):417-23. [Content Brief]

[4]. Dietrich DR, et al. Species- and sex-specific renal cytotoxicity of ochratoxin A and B in vitro. Exp Toxicol Pathol. 2001 Jun;53(2-3):215-25. [Content Brief]

[5]. Csenki Z, et al. The individual and combined effects of ochratoxin A with citrinin and their metabolites (ochratoxin B, ochratoxin C, and dihydrocitrinone) on 2D/3D cell cultures, and zebrafish embryo models. Food Chem Toxicol. 2021 Dec;158:112674. [Content Brief]

[6]. Mally A, et al. Biotransformation and nephrotoxicity of ochratoxin B in rats. Toxicol Appl Pharmacol. 2005 Aug 1;206(1):43-53. [Content Brief]

[7]. Størmer FC, et al. Metabolism of ochratoxin B and its possible effects upon the metabolism and toxicity of ochratoxin A in rats. Appl Environ Microbiol. 1985 May;49(5):1108-12. [Content Brief]